Long-term response of pituitary carcinoma to temozolomide. Report of two cases
- PMID: 17044568
- DOI: 10.3171/jns.2006.105.4.621
Long-term response of pituitary carcinoma to temozolomide. Report of two cases
Abstract
Pituitary carcinoma is a rare tumor characterized by poor responsiveness to therapy, leading to early death. Reported responses to standard chemotherapy have only been anecdotal, with no single agent or combination demonstrating consistent efficacy in the treatment of patients with this disease. The authors report rare examples of a persistent response to cytotoxic chemotherapy in two patients with pituitary carcinoma. One patient was a 38-year-old man with visual field loss caused by a luteinizing hormone-secreting pituitary carcinoma that had recurred despite multiple surgeries and radiation therapy. Intradural metastases to the spine that had failed to respond to radiation therapy were pathologically confirmed. The second patient was a 26-year-old man with hyperprolactinemia from a prolactin-secreting pituitary tumor. Spine magnetic resonance images obtained to search for causes of neck pain showed a vertebral tumor, which was later confirmed through pathological analysis to be a metastatic pituitary carcinoma. His disease progressed despite radiation therapy, high-dose bromocriptine, and chemotherapy. Both patients were treated monthly with temozolomide, which was administered orally on the first 5 days of a 28-day cycle. The patient in the first case underwent all 12 treatment cycles without serious side effects, and his visual field deficits improved. The patient in the second case had undergone only 10 cycles when the drug was stopped because of his severe fatigue. Nonetheless, his pain disappeared and his serum prolactin concentration decreased. Both patients continue to have partial responses and have been employed full-time for more than 1 year after discontinuing temozolomide therapy. These two examples demonstrate that temozolomide may be effective in treating pituitary carcinomas and thus should be considered in the treatment algorithm for these difficult cases.
Similar articles
-
Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.BMC Endocr Disord. 2021 Oct 29;21(1):217. doi: 10.1186/s12902-021-00874-8. BMC Endocr Disord. 2021. PMID: 34715828 Free PMC article. Review.
-
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.Pituitary. 2020 Aug;23(4):359-366. doi: 10.1007/s11102-020-01040-4. Pituitary. 2020. PMID: 32232709 Review.
-
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.Endocrinol Diabetes Nutr. 2017 Dec;64(10):564-566. doi: 10.1016/j.endinu.2017.08.007. Epub 2017 Nov 11. Endocrinol Diabetes Nutr. 2017. PMID: 29137963 English, Spanish. No abstract available.
-
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.J Oncol Pharm Pract. 2016 Jun;22(3):517-22. doi: 10.1177/1078155215569556. Epub 2015 Jan 23. J Oncol Pharm Pract. 2016. PMID: 25616657
-
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.Ann Endocrinol (Paris). 2012 Jun;73(3):225-9. doi: 10.1016/j.ando.2012.03.001. Epub 2012 Apr 20. Ann Endocrinol (Paris). 2012. PMID: 22520146
Cited by
-
Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.J Clin Endocrinol Metab. 2023 Jun 16;108(7):1585-1601. doi: 10.1210/clinem/dgad098. J Clin Endocrinol Metab. 2023. PMID: 36856733 Free PMC article.
-
Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case.J Neurosurg Case Lessons. 2023 Jan 16;5(3):CASE22363. doi: 10.3171/CASE22363. Print 2023 Jan 16. J Neurosurg Case Lessons. 2023. PMID: 36647250 Free PMC article.
-
Individualized medical treatment options in Cushing disease.Front Endocrinol (Lausanne). 2022 Dec 2;13:1060884. doi: 10.3389/fendo.2022.1060884. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36531477 Free PMC article. Review.
-
Pituitary Carcinoma in a Patient with Cowden Syndrome.Am J Case Rep. 2022 Feb 3;23:e934846. doi: 10.12659/AJCR.934846. Am J Case Rep. 2022. PMID: 35110519 Free PMC article.
-
Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.Front Endocrinol (Lausanne). 2021 Jun 16;12:650791. doi: 10.3389/fendo.2021.650791. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34220707 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical